- Home
- PBYI vs GCO Comparison
PBYI vs GCO Comparison
Compare PBYI & GCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PBYI | GCO |
|---|---|---|
| Founded | 2010 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.4M | 284.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PBYI | GCO |
|---|---|---|
| Price | $7.04 | $28.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.00 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 411.3K | 270.1K |
| Earning Date | 02-26-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.87 | N/A |
| EPS | ★ 0.74 | 0.00 |
| Revenue | $211,995,000.00 | ★ $2,382,104,000.00 |
| Revenue This Year | N/A | $5.42 |
| Revenue Next Year | N/A | $2.41 |
| P/E Ratio | ★ $9.16 | $8,017.07 |
| Revenue Growth | N/A | ★ 2.76 |
| 52 Week Low | $2.58 | $16.19 |
| 52 Week High | $7.21 | $42.16 |
Technical Indicators
Market Signals| Indicator | PBYI | GCO |
|---|---|---|
| Relative Strength Index (RSI) | 68.59 | 42.58 |
| Support Level | $6.27 | $28.51 |
| Resistance Level | $6.64 | $30.94 |
| Average True Range (ATR) | 0.32 | 1.90 |
| MACD | 0.01 | -0.88 |
| Stochastic Oscillator | 89.15 | 3.08 |
Price Performance
Historical ComparisonAbout PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About GCO Genesco Inc.
Genesco Inc. sells footwear, headwear, sports apparel, and accessories through four main segments. The Journeys Group generates the highest revenue, encompassing the Journeys, Journeys Kidz, and Little Burgundy brands, along with e-commerce and catalog sales. The Schuh Group targets teenagers and young adults aged 16 to 24, focusing on casual and athletic footwear. The Johnston & Murphy Group operates retail shops and factory stores across the United States. Finally, the Genesco Brands Group designs and sources licensed footwear for brands like Levi's, Dockers, and G.H. Bass.